ALC Stock Forecast & Price Target

Alcon is well positioned to sustain mid-single digit revenue growth, supported by leadership in contact lenses, ocular health, and surgical devices, plus recent product launches that are already lifting share and utilization. The Neurotech acquisition adds a potentially meaningful new growth driver: ENCELTO launched in the US in 1Q25, had about 700 patients enrolled in 1Q26, and could scale from roughly $150M in 2026 sales toward $500M+ in 2028. Alongside improving market access, a large installed base, and margin expansion that could drive double-digit EPS growth, these fundamentals support a constructive view on the stock.

Alcon is challenged by the risk that its visioncare and surgical franchises grow only flat to low-single digits, especially if it loses share in IOLs or contact lenses and new-product adoption stays weak. Even with FY26 net sales guidance of $10.927B to $11.134B and core EPS of $3.49 to $3.58, margin expansion appears limited to 20.7%-21.7%, while tariff headwinds of about $40M-$90M and elevated costs can pressure profitability. With slower operating leverage, a PowerVision write-off of $402M, and dependence on a market growing only 3%-4%, the stock’s fundamentals suggest muted earnings momentum and limited upside.